Dyslipidemia Market Strategic Insights and key Business Influencing Factors | Major Players – Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals.
Dyslipidemia Marketis a condition in which the levels of lipids (cholesterol, triglycerides, or both) or low high-density lipoprotein (HDL) cholesterol level elevated due to multiple reasons including lifestyle, genetics-disorders, drugs etc. According to World Health Organization, there were approximately 17.9 million people in 2016, who died from cardiovascular diseases, almost more than half of these cases could have been avoided with the availability of proper medical treatment. This significant number is expected to act as a driver to the market growth.
Global Dyslipidemia is expected to rise gradually to an estimated value of USD 27.52 billion by 2026, registering a CAGR of 10.50% in the forecast period of 2019-2026 with the annual sales of USD 12.38 billion in the year of 2018. This rise in market value can be attributed to the increase in prevalence and awareness along with concerns regarding the health of patients.
Get Sample Report at :
https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-dyslipidemia-market
Competitive Analysis: Global Dyslipidemia Market
Few of the major competitors currently working in Global Dyslipidemia Market are AstraZeneca (UK), Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis, Cipla Inc., CJ HealthCare, CKD Bio, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, JW Pharmaceuticals, Kadmon Pharmaceuticals, Lupin Pharmaceuticals and few among others.
Key Pointers Covered in the Global Dyslipidemia Market Trends and Forecast to 2026
- Global Dyslipidemia Market New Sales Volumes
- Global Dyslipidemia Market Replacement Sales Volumes
- Global Dyslipidemia Market Installed Base
- Global Dyslipidemia Market By Brands
- Global Dyslipidemia Market Size
- Global Dyslipidemia Market Procedure Volumes
- Global Dyslipidemia Market Product Price Analysis
- Global Dyslipidemia Market Healthcare Outcomes
- Global Dyslipidemia Market Cost of Care Analysis
- Global Dyslipidemia Market Regulatory Framework and Changes
- Global Dyslipidemia Market Prices and Reimbursement Analysis
- Global Dyslipidemia Market Shares in Different Regions
- Recent Developments for Global Dyslipidemia Market Competitors
- Global Dyslipidemia Market Upcoming Applications
- Global Dyslipidemia Market Innovators Study
Get Detailed TOC:
https://www.databridgemarketresearch.com/toc/?dbmr=global-dyslipidemia-market
Key Developments in the Market:
- In the year 2018, Sanofi and Regeneron Pharmaceuticals, Inc. announced that Praluent (alirocumab) in phase 3 clinical trialdemonstrated the risk of major adverse cardiovascular events (MACE) in patients who had suffered a recent acute coronary syndrome (ACS) event such as a heart attack.
- In the year 2018, Amgen Inc. announced the launch of Repatha (Evolocumab) in the US for the indication of heart attacks and stroke due to high cholesterol at a reduced price to gain more customers.
- In the year 2015, WuXi PharmaTech announced its partnership with Eli Lilly to develop, manufacture, and commercializes in China a Lilly-discovered oral experimental drug for cardiovascular risk in patients with dyslipidemia.
Market Drivers
- Increase in global geriatric population
- Increase in prevalence of lifestyle diseases
- Rise in acceptance of telemental health
- Increase in availability of generic drugs
Market Restraints
- Lack of R&D initiatives in this area.
- patent expiry for some blockbuster drugs
- Fewer Government initiatives taken in this direction.
Inquire Before Buying:
https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-dyslipidemia-market
Key insights in the report:
- Complete and distinct analysis of the market drivers and restraints
- Key Market players involved in this industry
- Detailed analysis of the Market Segmentation
- Competitive analysis of the key players involved
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
Browse Related Report Here: